Cargando…

Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis

OBJECTIVE: Aripiprazole and risperidone are 2 of the most used second-generation antipsychotics (SGAs) worldwide. Previous evidence shows a similar effect of these SGAs on weight and metabolic changes in the short term. However, a longer period is necessary for a better assessment of the SGA´s metab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vázquez-Bourgon, Javier, Ortiz-García de la Foz, Víctor, Gómez-Revuelta, Marcos, Mayoral-van Son, Jacqueline, Juncal-Ruiz, María, Garrido-Torres, Nathalia, Crespo-Facorro, Benedicto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Regular Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593219/ https://www.ncbi.nlm.nih.gov/pubmed/35641112 http://dx.doi.org/10.1093/ijnp/pyac033

Ejemplares similares

Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial
por: Garrido-Sánchez, Lucía, et al.
Publicado: (2022)

Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone
por: Gómez-Revuelta, Marcos, et al.
Publicado: (2018)

Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone
por: Gómez-Revuelta, Marcos, et al.
Publicado: (2020)

Expression and Functionality Study of 9 Toll-Like Receptors in 33 Drug-Naïve Non-Affective First Episode Psychosis Individuals: A 3-Month Study
por: Juncal-Ruiz, Maria, et al.
Publicado: (2020)

Treatment Discontinuation Impact on Long-Term (10-Year) Weight Gain and Lipid Metabolism in First-Episode Psychosis: Results From the PAFIP-10 Cohort
por: Vázquez-Bourgon, Javier, et al.
Publicado: (2020)

Understanding sex differences in long-term outcomes after a first episode of psychosis
por: Ayesa-Arriola, Rosa, et al.
Publicado: (2020)

Pattern of long-term weight and metabolic changes after a first episode of psychosis: Results from a 10-year prospective follow-up of the PAFIP program for early intervention in psychosis cohort
por: Vázquez-Bourgon, J., et al.
Publicado: (2022)

The effect of excess weight on circulating inflammatory cytokines in drug-naïve first-episode psychosis individuals
por: Juncal-Ruiz, María, et al.
Publicado: (2018)

Data regarding active psychosis and functional outcome, among other clinical variables, during early phases of the illness in first-episode psychosis in the PAFIP 10-year follow-up program
por: Pardo-de-Santayana, Guillermo, et al.
Publicado: (2020)

Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review
por: Crespo-Facorro, Benedicto, et al.
Publicado: (2016)

Data regarding the effect of cannabis consumption on liver function in the prospective PAFIP cohort of first episode psychosis
por: Vázquez-Bourgon, Javier, et al.
Publicado: (2019)

T175. A 10-YEAR LONGITUDINAL STUDY OF GREY MATTER VOLUME IN FIRST EPISODE OF NON-AFFECTIVE PSYCHOSIS
por: Tordesillas-Gutiérrez, Diana, et al.
Publicado: (2018)

Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis
por: Crespo-Facorro, Benedicto, et al.
Publicado: (2021)

S101. DIFFERENTIATING NON-AFFECTIVE ACUTE REMITTING PSYCHOSIS (NARP) FROM SCHIZOPHRENIA IN FIRST-EPISODE PSYCHOSIS: FINDINGS FROM A 3-YEAR LONGITUDINAL STUDY IN THE PAFIP COHORT
por: López-Díaz, Álvaro, et al.
Publicado: (2020)

Effects of Risperidone on Cytokine Profile in Drug-Naïve First-Episode Psychosis
por: Noto, Cristiano, et al.
Publicado: (2015)

Cervical cancer screening and psychosis: a longitudinal retrospective study comparing women with schizophrenia spectrum disorders and the general population
por: Vázquez-Bourgon, Javier, et al.
Publicado: (2022)

Polygenic risk scores enhance prediction of body mass index increase in individuals with a first episode of psychosis
por: Muntané, Gerard, et al.
Publicado: (2023)

Longitudinal trajectories in negative symptoms and changes in brain cortical thickness: 10-year follow-up study
por: Canal-Rivero, Manuel, et al.
Publicado: (2023)

A Disrupted-in-Schizophrenia 1 Gene Variant is Associated with Clinical Symptomatology in Patients with First-Episode Psychosis
por: Vázquez-Bourgon, Javier, et al.
Publicado: (2014)

Long-Term Grey Matter Changes in First Episode Psychosis: A Systematic Review
por: Gallardo-Ruiz, Ruth, et al.
Publicado: (2019)

O6.7. COMMON NEUROANATOMICAL ABNORMALITIES IN FIRST EPISODE PSYCHOSIS ACROSS SEVERAL INDEPENDENT SAMPLES
por: Vieira, Sandra, et al.
Publicado: (2018)

S124. RECOVERY TRAJECTORIES IN FIRST EPISODE PSYCHOSIS PATIENTS: THE ROLE OF TIMING
por: Ayesa-Arriola, Rosa, et al.
Publicado: (2018)

Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naive first-episode psychosis patients
por: Birur, Badari, et al.
Publicado: (2020)

S153. WHERE IS THE ABNORMAL BRAIN ACTIVITY IN FIRST EPISODE PSYCHOSIS?
por: Pau, Soldevila-Matias, et al.
Publicado: (2018)

T72. VERBAL MEMORY AND VOXEL BASED MORPHOMETRY IN FIRST EPISODE NON-AFFECTIVE PSYCHOSIS: A PROCESS ORIENTED APPROACH
por: Ayesa-Arriola, Rosa, et al.
Publicado: (2018)

F124. SEX DIFFERENCES IN OUTCOME IN FIRST EPISODE PSYCHOSIS PATIENTS: A 10-YEAR FOLLOW-UP STUDY
por: Ayesa-Arriola, Rosa, et al.
Publicado: (2018)

Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia
por: Ranjbar, Fatemeh, et al.
Publicado: (2015)

Intelligence Quotient changes over 10 years: diversity of cognitive profiles in first episode of psychosis and healthy controls
por: Murillo-Garcia, N., et al.
Publicado: (2023)

The right occipital lobe and poor insight in first-episode psychosis
por: Tordesillas-Gutierrez, Diana, et al.
Publicado: (2018)

F81. AGE OF ONSET OF CANNABIS USE AND COGNITIVE FUNCTION IN FIRST EPISODE NON-AFFECTIVE PSYCHOSIS PATIENTS: 3-YEAR FOLLOW-UP OUTCOME
por: Setién-Suero, Esther, et al.
Publicado: (2018)

Neuroanatomical Differences between First-Episode Psychosis Patients with and without Neurocognitive Deficit: A 3-Year Longitudinal Study
por: Ayesa-Arriola, Rosa, et al.
Publicado: (2013)

S173. GREY MATTER VOLUME DEFFICITS IN PATIENTS WITH A FIRST EPISODE NON-AFFECTIVE PSYCHOSIS AND SUICIDE RELATED BEHAVIOUR
por: Tordesillas-Gutiérrez, Diana, et al.
Publicado: (2018)

F145. WHAT ARE THE MAIN BRAIN CHANGES IN FMRI AFTER TREATMENT IN FIRST EPISODE PSYCHOSIS? A SYSTEMATIC REVIEW
por: Gonzalez, Carlos, et al.
Publicado: (2018)

Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study
por: Sanchez-Gistau, Vanessa, et al.
Publicado: (2023)

Cannabis use in male and female first episode of non-affective psychosis patients: Long-term clinical, neuropsychological and functional differences
por: Setién-Suero, Esther, et al.
Publicado: (2017)

Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania
por: Rezayat, Amir Akhavan, et al.
Publicado: (2014)

Neuroanatomical abnormalities in first-episode psychosis across independent samples: a multi-centre mega-analysis
por: Vieira, Sandra, et al.
Publicado: (2021)

F101. CANNABIS USE AND HEPATIC STEATOSIS IN PSYCHOSIS: RESULTS FROM A 3-YEAR LONGITUDINAL STUDY
por: Vázquez-Bourgon, Javier, et al.
Publicado: (2018)

Effect of Aripiprazole on Cognitive Function and Hyperprolactinemia in Patients with Schizophrenia Treated with Risperidone
por: Lee, Bong Ju, et al.
Publicado: (2013)

A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia
por: Pandey, Ravi S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lt2eo8hinoq9i3kejo3k02igb9